CR20230119A - Flt3 ligand fusion proteins and methods of use - Google Patents

Flt3 ligand fusion proteins and methods of use

Info

Publication number
CR20230119A
CR20230119A CR20230119A CR20230119A CR20230119A CR 20230119 A CR20230119 A CR 20230119A CR 20230119 A CR20230119 A CR 20230119A CR 20230119 A CR20230119 A CR 20230119A CR 20230119 A CR20230119 A CR 20230119A
Authority
CR
Costa Rica
Prior art keywords
methods
fusion proteins
flt3 ligand
ligand fusion
effectorless
Prior art date
Application number
CR20230119A
Other languages
Spanish (es)
Inventor
Christine Carine Moussion
Travis William Bainbridge
Christopher Charles Kemball
Jill M Schartner
Gregory Alan Lazar
Sivan Cohen
Yichin Liu
Iraj Hosseini
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CR20230119A publication Critical patent/CR20230119A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides an effectorless immunoglobulin Fc protein, fusions of the effectorless Fc protein to a Flt3 ligand, and methods of using the same.
CR20230119A 2020-08-07 2021-08-05 Flt3 ligand fusion proteins and methods of use CR20230119A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063062713P 2020-08-07 2020-08-07
PCT/US2021/044586 WO2022031876A1 (en) 2020-08-07 2021-08-05 Flt3 ligand fusion proteins and methods of use

Publications (1)

Publication Number Publication Date
CR20230119A true CR20230119A (en) 2023-05-16

Family

ID=77519822

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230119A CR20230119A (en) 2020-08-07 2021-08-05 Flt3 ligand fusion proteins and methods of use

Country Status (18)

Country Link
US (2) US11542308B2 (en)
EP (1) EP4192854A1 (en)
JP (1) JP7847578B2 (en)
KR (1) KR20230042596A (en)
CN (1) CN116234830A (en)
AR (1) AR123158A1 (en)
AU (1) AU2021322239A1 (en)
BR (1) BR112023002123A2 (en)
CA (1) CA3188426A1 (en)
CL (1) CL2023000381A1 (en)
CO (1) CO2023001488A2 (en)
CR (1) CR20230119A (en)
IL (1) IL300260A (en)
MX (2) MX2023001441A (en)
PE (1) PE20230983A1 (en)
TW (1) TW202221016A (en)
WO (1) WO2022031876A1 (en)
ZA (1) ZA202300862B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20230119A (en) * 2020-08-07 2023-05-16 Genentech Inc Flt3 ligand fusion proteins and methods of use
TW202313094A (en) 2021-05-18 2023-04-01 美商基利科學股份有限公司 Methods of using flt3l-fc fusion proteins
JP7673255B2 (en) 2021-06-11 2025-05-08 ギリアード サイエンシーズ， インコーポレイテッド Combination of MCL-1 inhibitors with antibody drug conjugates
TWI910028B (en) 2021-06-11 2025-12-21 美商基利科學股份有限公司 Combination mcl-1 inhibitors with anti-cancer agents
US20250340607A1 (en) * 2022-06-03 2025-11-06 The University Of Chicago Antigen tolerance induction through use of flt3l variants

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
MD1367C2 (en) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Methods of B-cells lymphoma treatment, anti-CD20 antibodies, hybridoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US7294331B2 (en) 1994-03-07 2007-11-13 Immunex Corporation Methods of using flt3-ligand in hematopoietic cell transplantation
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
ATE296315T1 (en) 1997-06-24 2005-06-15 Genentech Inc COMPOSITIONS CONTAINING GALACTOSYLATED GLYCOPROTEINS AND METHOD FOR THE PRODUCTION THEREOF
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
ES2434961T5 (en) 1998-04-20 2018-01-18 Roche Glycart Ag Antibody glycosylation engineering to improve antibody-dependent cell cytotoxicity
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CN100427603C (en) 1999-10-04 2008-10-22 麦迪卡格公司 Method for regulating transcription of exogenous gene
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
ATE344801T1 (en) 1999-12-29 2006-11-15 Immunogen Inc CYTOTOXIC AGENTS CONTAINING DOXORUBICIN AND DAUNORUBICIN AND THEIR THERAPEUTIC USE
ES2639222T5 (en) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Cells that produce antibody compositions
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
US7368114B2 (en) 2001-10-25 2008-05-06 The United States Of America As Represented By The Department Of Health And Human Services Fusion protein including of CD4
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003224810B2 (en) * 2002-03-26 2006-08-31 Immunex Corporation Methods of using Flt3-ligand in immunization protocols
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
JP4832719B2 (en) 2002-04-09 2011-12-07 協和発酵キリン株式会社 Medicine containing antibody composition for FcγRIIIa polymorphism patients
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
EA200401325A1 (en) 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. CELLS WITH MODIFIED GENOM
ATE503829T1 (en) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd CELL WITH REDUCED OR DELETED ACTIVITY OF A PROTEIN INVOLVED IN GDP-FUCOSE TRANSPORT
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20050232931A1 (en) 2003-06-13 2005-10-20 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
JPWO2005035778A1 (en) 2003-10-09 2006-12-21 協和醗酵工業株式会社 Method for producing antibody composition using RNA that suppresses function of α1,6-fucosyltransferase
ES2672640T3 (en) 2003-11-05 2018-06-15 Roche Glycart Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2005053742A1 (en) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Medicine containing antibody composition
JP2008527980A (en) * 2005-01-25 2008-07-31 アポロ ライフ サイエンシズ リミテッド Molecule and its chimeric molecule
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
DE102008061522A1 (en) 2008-12-10 2010-06-17 Biontech Ag Use of Flt3 ligand to enhance immune responses in RNA immunization
CA2822366A1 (en) * 2010-12-23 2012-06-28 Janssen Biotech, Inc. Active protease-resistant antibody fc mutants
GB201107170D0 (en) 2011-04-28 2011-06-15 Clark Michael Binding molecules with biased recognition
EP3385277A1 (en) 2013-03-15 2018-10-10 F. Hoffmann-La Roche AG Il-22 polypeptides and il-22 fc fusion proteins and methods of use
US11369663B2 (en) * 2016-06-07 2022-06-28 Washington University Detection of CD5 and methods and compositions for modulating CD5
MY200602A (en) * 2016-07-14 2024-01-04 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
CN110214147A (en) * 2016-10-14 2019-09-06 Xencor股份有限公司 IL15/IL15R α heterodimer FC- fusion protein
US11246908B2 (en) 2018-01-10 2022-02-15 The Johns Hopkins University Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof
AU2019234642A1 (en) * 2018-03-13 2020-09-24 Memorial Sloan Kettering Cancer Center Oncolytic vaccinia virus expressing immune checkpoint blockade for cancer immunotherapy
US10780121B2 (en) * 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
WO2020069382A1 (en) 2018-09-28 2020-04-02 Lyvgen Biopharma Co., Ltd. Anti-cd137 binding molecules having engineered fc domains and therapeutic uses thereof
JP7626698B2 (en) * 2018-09-28 2025-02-04 リビジェン バイオファーマ ホールディングス リミテッド Anti-cd40 binding molecules with engineered fc domains and therapeutic uses thereof
JP7729778B2 (en) * 2019-03-28 2025-08-26 オリオニス バイオサイエンシズ，インコーポレイテッド Chimeric proteins and chimeric protein complexes directed against FMS-like tyrosine kinase 3 (FLT3)
CR20210687A (en) * 2019-06-25 2022-03-03 Gilead Sciences Inc FLT3L-Fc FUSION PROTEINS AND METHODS OF USE
PE20231104A1 (en) * 2020-07-21 2023-07-19 Genentech Inc BRM ANTIBODY CONJUGATED CHEMICAL DEGRADATION INDUCERS AND METHODS THEREOF
CR20230119A (en) * 2020-08-07 2023-05-16 Genentech Inc Flt3 ligand fusion proteins and methods of use

Also Published As

Publication number Publication date
CL2023000381A1 (en) 2023-07-28
TW202221016A (en) 2022-06-01
IL300260A (en) 2023-03-01
KR20230042596A (en) 2023-03-28
ZA202300862B (en) 2025-05-28
CA3188426A1 (en) 2022-02-10
US20220289803A1 (en) 2022-09-15
JP2023536655A (en) 2023-08-28
US11542308B2 (en) 2023-01-03
BR112023002123A2 (en) 2023-03-07
AR123158A1 (en) 2022-11-02
US20230279067A1 (en) 2023-09-07
WO2022031876A1 (en) 2022-02-10
CN116234830A (en) 2023-06-06
CO2023001488A2 (en) 2023-02-16
MX2023001440A (en) 2023-03-06
JP7847578B2 (en) 2026-04-17
EP4192854A1 (en) 2023-06-14
AU2021322239A1 (en) 2023-02-23
PE20230983A1 (en) 2023-06-21
MX2023001441A (en) 2023-03-06

Similar Documents

Publication Publication Date Title
ZA202300862B (en) Flt3 ligand fusion proteins and methods of use
MY205418A (en) Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
WO2020247843A8 (en) Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
ZA202300423B (en) Fusion constructs and methods of using thereof
EA202091239A1 (en) FUSION PROTEIN BASED ON A THERAPEUTIC ENZYME WITH A NEW STRUCTURE AND ITS APPLICATION
MX2020010912A (en) Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof.
EP4659757A3 (en) Multi-chain chimeric polypeptides and uses thereof
SA521421825B1 (en) (GLP1) fusion proteins of glucagon-like peptide 1 (GDF15) and growth differentiation factor 15 and its use
MX2021000263A (en) SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF.
WO2020077276A3 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
MX2018001787A (en) Gitrl fusion proteins and uses thereof.
MX2021000047A (en) Pd1-4-1bbl variant fusion protein and methods of use thereof.
MX2020010910A (en) Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof.
TW200732350A (en) Methods for generating monovalent IgG
PH12017502025A1 (en) Fusion proteins
MY202559A (en) Anti-ctla-4 antibody and use thereof
SG11202006259SA (en) Il-22 fc fusion proteins and methods of use
AU2018249796A1 (en) Antibody Fc variants for improving blood half-life
EA201591407A1 (en) ANTIBODIES CONTAINING CHEMICAL CONSTANT DOMAINS
AU2018226215B2 (en) Immunoconjugates with optimized linkers and orientation
SG10201903142RA (en) Serpin fusion polypeptides and methods of use thereof
EP4273161A4 (en) Protein containing heterodimer antibody fc, and preparation method therefor
MX2017010359A (en) Fc-FUSED HIGH AFFINITY IgE RECEPTOR a-CHAIN.
WO2019090215A3 (en) Dominant negative ligand chimeric antigen receptor systems
MX2025002123A (en) Fusion protein comprising taci polypeptide and use thereof